Results 131 to 140 of about 20,228 (237)

Tirzepatide‐induced body composition changes: Implications from the SURPASS‐3 MRI substudy

open access: yes
Journal of Diabetes Investigation, EarlyView.
I‐Weng Yen, Hung‐Yuan Li
wiley   +1 more source

Cell Calcification Models and Their Implications for Medicine and Biomaterial Research

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 6, 9 February 2026.
Calcification, is the process by which the tissues containing minerals are formed, occurring during normal physiological processes, or in pathological conditions. Here, it is aimed to give a comprehensive overview of the range of cell models available, and the approaches taken by these models, highlighting when and how methodological divergences arise,
Luke Hunter   +5 more
wiley   +1 more source

Novel Vascularized Human Liver Organoids for Modeling Alcohol‐Induced Liver Injury and Developing Hepatoprotective Therapy

open access: yesAdvanced Science, Volume 13, Issue 9, 13 February 2026.
This study successfully engineered vascularized liver organoids (3HLOs) by co‐culturing human reprogrammed hepatocyte‐like cells (hrHLs) with human umbilical vein endothelial cells (HUVECs) and human umbilical mesenchymal stem cells (HUMSCs). Upon implantation, the 3HLOs established functional vascular anastomosis with the host circulation and ...
Kangdi Yang   +13 more
wiley   +1 more source

Interplay between ALK2R206H mutant receptor and autophagy signaling regulates receptor stability and its chondrogenic functions

open access: yesCell Death Discovery
Heterozygous mutations in the Bone morphogenetic protein (BMP) type I receptor ACVR1, encoding activin-like kinase 2 (ALK2), underlie all cases of the rare genetic musculoskeletal disorder Fibrodysplasia Ossificans Progressiva (FOP).
Laura Coculo   +15 more
doaj   +1 more source

Parabiosis, Assembloids, Organoids (PAO)

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
This review evaluates parabiosis, organoids, and assembloids as complementary disease models spanning systemic, organ, and multi‐organ levels. It highlights their construction strategies, applications, and current limitations, while emphasizing their integration with frontier technologies such as artificial intelligence, organ‐on‐a‐chip, CRISPR, and ...
Yang Hong   +5 more
wiley   +1 more source

Activins in reproductive biology and beyond.

open access: yesHuman Reproduction Update, 2016
R. Wijayarathna   +2 more
semanticscholar   +1 more source

Surface‐Associated Proteins on Extracellular Vesicles Remodel the Tumor Microenvironment by Potentiating TGF‐β Signaling in a Contact‐Dependent Manner

open access: yesAdvanced Science, Volume 13, Issue 8, 9 February 2026.
Extracellular vesicles (EVs) released from TGF‐β‐activated CAFs are enriched with ECM proteins such as TSG6 and THBS1, which facilitate their binding to recipient cell membranes. This EV–cell interaction promotes the clustering of CD44 and TGF‐β receptors on the target cell surface, thereby potentiating TGF‐β signaling activity. This study highlights a
Chao Li   +7 more
wiley   +1 more source

Antiviral activity of bone morphogenetic proteins and activins

open access: yesNature Microbiology, 2018
L. Eddowes   +29 more
semanticscholar   +1 more source

Generation and characterization of iPSC‐derived microglia for in vitro modeling of stimuli‐specific neuroimmune responses

open access: yesAlzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Microglia are macrophage‐like brain resident immune cells known to express numerous Alzheimer's disease risk genes. Here we generated a human induced pluripotent stem cell (iPSC) derived microglia cell culture model for use in neuroimmune modeling and therapeutic testing.
Angela K. Haskell   +16 more
wiley   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 535-544, February 2026.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy